Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells

Prognosis and survival of patients with hepatocellular carcinoma (HCC) is still very poor, and no therapies are currently available to inhibit tumour growth and metastases. Recently, we reported that the expression of an extracellular matrix component (ECM), namely Laminin-5 (Ln-5), is directly rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannelli, G, Azzariti, A, Fransvea, E, Porcelli, L, Antonaci, S, Paradiso, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409763/
https://www.ncbi.nlm.nih.gov/pubmed/15545972
http://dx.doi.org/10.1038/sj.bjc.6602231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409763/
https://www.ncbi.nlm.nih.gov/pubmed/15545972
http://dx.doi.org/10.1038/sj.bjc.6602231

Ejemplares similares